NCT04439968

Brief Summary

Implementing target ranges for regional cerebral saturations in extremely preterm infants in the first week of life may improve neurodevelopmental outcomes at 22-26 months corrected age compared to those without targeted cerebral saturations (Csat) using near-infrared spectroscopy (NIRS). Infants will be randomized to a targeted cerebral saturation monitoring group with visible reading of Csat or to a control group with cerebral saturation monitoring, but with blinded Csat measures. Those in the targeted Csat group will follow a treatment guideline to maintain cerebral oxygenation in the target range. The primary outcome is neurodevelopmental outcome as determined by Bayley III cognitive scale score.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Aug 2021

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 15, 2020

Completed
4 days until next milestone

First Posted

Study publicly available on registry

June 19, 2020

Completed
1.1 years until next milestone

Study Start

First participant enrolled

August 10, 2021

Completed
4.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2025

Completed
Last Updated

April 18, 2024

Status Verified

April 1, 2024

Enrollment Period

4.4 years

First QC Date

June 15, 2020

Last Update Submit

April 16, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • Neurodevelopmental outcome

    Neurodevelopmental outcomes will be assessed using the cognitive component of the Bayley Scales of Infant Development-III at 22-26 months of age. Scores range from 55-145 with higher number representing a better neurodevelopmental outcome.

    22-26 months of age

Secondary Outcomes (2)

  • Death

    from birth until hospital discharge, an average of 3 months.

  • Retinopathy of prematurity

    from birth until hospital discharge, an average of 3 months.

Other Outcomes (1)

  • Burden of Cerebral hypoxia or hyperoxia

    From birth until first 7 days of life

Study Arms (2)

Targeted Csats

ACTIVE COMPARATOR

Subjects randomized to the targeted Csat arm will have NIRS monitoring of cerebral saturations (Csat) and will have algorithm-driven clinical interventions to maintain Csat within target range in the first week of life.

Other: Clinical algorithm

Non-targeted Csats

NO INTERVENTION

Subjects randomized to the non-targeted Csat arm will have NIRS (near-infrared spectroscopy) monitoring of Csats, but Csat values will be obscured and not available to providers. These subjects will not have any algorithm-driven clinical interventions for Csat.

Interventions

In order to maintain cerebral saturations within targeted range, subjects in the targeted Csat arm will undergo clinical interventions based on clinical algorithm. Interventions may include administration of inotropes, fluid resuscitation, transfusion of blood products, and/or adjustment to respiratory support.

Targeted Csats

Eligibility Criteria

AgeUp to 2 Days
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • Very preterm infants with gestational age at least 23 weeks but less than 29 completed weeks
  • Less than 6 hours of age

You may not qualify if:

  • Skin integrity insufficient to allow placement of NIRS sensors
  • Decision not to provide full intensive care support
  • Congenital condition, other than premature birth, that adversely affects life expectancy or neurodevelopment

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Lucile Packard Children's Hospital Stanford

Palo Alto, California, 94304, United States

Location

MeSH Terms

Conditions

Hypoxia, Brain

Condition Hierarchy (Ancestors)

Brain DiseasesCentral Nervous System DiseasesNervous System DiseasesHypoxiaSigns and Symptoms, RespiratorySigns and SymptomsPathological Conditions, Signs and Symptoms

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Masking Details
Assessors of neurodevelopmental outcome are blinded to targeted vs non-targeted monitoring
Purpose
DIAGNOSTIC
Intervention Model
PARALLEL
Model Details: randomized to 2 groups: Targeted NIRS monitoring vs Non-targeted, blinded NIRS monitoring
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

June 15, 2020

First Posted

June 19, 2020

Study Start

August 10, 2021

Primary Completion

December 31, 2025

Study Completion

December 31, 2025

Last Updated

April 18, 2024

Record last verified: 2024-04

Locations